EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The spectrum of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis and MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD. Case-finding strategies for MASLD with liver fibrosis, using non-invasive tests, should be applied in individuals with…

• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• GS
  Gilead Sciences
• AP
  Alnylam Pharmaceuticals
• D
  Danone
• CB
  CSL Behring
• NB
  NGM Biopharmaceuticals
• CB
  Coherus Biosciences
• FW
  Fonds Wetenschappelijk Onderzoek
• E
  Eisai
• NN
  Novo Nordisk
• AP
  Astellas Pharma
• EA
  European Association for the Study of Diabetes
• EA
  European Association for the Study of the Liver
• SH
  Siemens Healthineers
• VR
  Vlaamse regering
• I
  Ipsen
• DF
  Dr. Falk Pharma
• A
  Allergan
• C
  Cilag